Kythera Labs Competitive Intelligence & Landscape
kytheralabs.com ·
Overview
Kythera Labs Overview
Kythera Labs serves a broad target market including hospitals, pharmaceutical companies, healthcare technology firms, and government entities, providing solutions that support clinical, commercial, and operational decision-making. The company's core services include data integration, enrichment, machine learning, and analytics, with a focus on improving patient outcomes and market understanding (Exa). With a team of around 34 employees, Kythera Labs emphasizes trust, innovation, and leveraging real-world data to solve complex healthcare challenges. Its mission centers on enabling healthcare organizations to uncover insights from massive datasets, ultimately fostering more confident and effective healthcare decisions (cbinsights.com).
Sources
Kythera Labs | Data Technology for Confident Healthcare Decisions
kytheralabs.com
About Kythera Labs | Healthcare Data Technology Company
kytheralabs.com
Kythera Labs - Products, Competitors, Financials, Employees, Headquarters Locations
cbinsights.com
Frequently Asked Questions About Kythera Labs
kytheralabs.com
Real-World Answers for Better Decision-Making
kytheralabs.com
Kythera Labs
kytheralabs.com
Kythera Labs Builds Business on Spark Declarative Pipelines | Databricks
databricks.com
Kythera Labs
cn.linkedin.com
Kythera Labs Weekly Intel Updates
Receive weekly intel updates about Kythera Labs straight to your inbox.
Competitors
Kythera Labs Competitors
Tuva Health is another significant competitor, focusing on claims and medical record data normalization, unification, and quality testing to support analytics and AI development. Its services are tailored toward enabling healthcare organizations to leverage raw data effectively for operational and strategic insights (CB Insights). Compared to Kythera Labs, Tuva emphasizes data quality and AI readiness, with a market position centered on data preparation and enrichment, which complements Kythera’s more comprehensive data integration and analytics platform.
Eccovia is a notable player in healthcare data management, offering solutions that integrate multiple data sources for care coordination, population health, and analytics. Its platform is designed to improve care delivery and health outcomes through data sharing and analytics, making it a direct competitor in the healthcare data infrastructure space (CB Insights). Eccovia's market focus on care coordination and population health management aligns closely with Kythera Labs' mission, but it tends to emphasize care delivery improvements.
In addition, IQVIA is a major player in health analytics with a broad portfolio that includes data, technology, and contract research services. Its market share in health analytics is significant, and it competes with Kythera Labs through extensive data assets and advanced analytics capabilities (6sense). IQVIA’s large scale, global presence, and diverse service offerings give it a competitive edge over smaller firms like Kythera Labs, especially in terms of market share and resource availability. Overall, these competitors differentiate themselves through specialized focus areas, data quality, and scale, shaping a competitive landscape for Kythera Labs in healthcare analytics.
Sources
IQVIA - Market Share, Competitor Insights in Health Analytics - 6Sense
6sense.com
Top Kythera Labs Alternatives, Competitors - CB Insights
cbinsights.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors
tracxn.com
Kythera Labs: Revenue, Competitors, Alternatives - Growjo
growjo.com
Hospitals and Health Systems Unlock Market Intelligence ...
kytheralabs.com
Top Centene (CNC) Competitors 2026 - MarketBeat
marketbeat.com
Kythera Labs - Products, Competitors, Financials, Employees, Headquarters Locations
cbinsights.com
Product & Pricing
Kythera Labs Product and Pricing Intelligence
Regarding pricing, Kythera Labs emphasizes transparency and flexible deployment options, including SaaS and data analysis platforms like Wayfinder, which facilitate secure data access and integration. While specific pricing tiers or plans are not detailed in the available sources, Kythera Labs' offerings are tailored to organizational needs, supporting both small teams and large enterprises with scalable data solutions (Kythera Labs) and strategic partnerships that enhance data utilization (Kythera Labs).
Recent developments highlight their focus on transforming complex healthcare data into actionable insights, with partnerships like HPC to improve price transparency and market analysis, and technological innovations such as Delta Sharing to reduce costs and improve data sharing efficiency (Databricks, Kythera Labs). While exact current pricing plans and tiers are not publicly disclosed, Kythera Labs’ offerings are positioned as flexible, purpose-built solutions designed to meet the complex needs of healthcare data analysis and strategic planning.
Sources
Kythera Labs | Data Technology for Confident Healthcare Decisions
kytheralabs.com
HPC and Kythera Labs Partner to Turn Price Transparency Data into ...
kytheralabs.com
Industry Solutions for Healthcare Data | Kythera Labs
kytheralabs.com
Pricing Transparency: The Current State of Affairs - Kythera Labs
kytheralabs.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors
tracxn.com
Kythera Labs End User License Agreement
kytheralabs.com
How Kythera Labs, a Databricks Built-On Partner, saves $2M+/year ...
databricks.com
Real-World Answers for Better Decision-Making
kytheralabs.com
Ad Campaigns
Kythera Labs Ad Campaigns
Kythera Labs is currently running 44 ads across LinkedIn — 44 on LinkedIn. Explore Kythera Labs's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.
See of Kythera Labs's ads
Browse the live creative across Google, Meta & LinkedIn in the ad library
Hiring & Layoffs
Kythera Labs Hiring and Layoffs
Recently, Kythera Labs appointed Glynn Dennis, Jr., Ph.D., as Chief Science Officer in December 2023, emphasizing their commitment to advancing research and development within the life sciences sector (Kythera Labs news). The company’s hiring pattern, which includes executive-level appointments and a focus on expanding their technical and scientific leadership, signals a strategic emphasis on innovation and growth in healthcare data analytics.
Regarding layoffs, there is no publicly available information indicating recent layoffs at Kythera Labs. Their recent activities, including rapid growth, funding, and strategic hires, suggest a company focused on expansion rather than downsizing. Their hiring trends and strategic investments reflect a company positioning itself for long-term growth in healthcare technology and data analytics, aiming to enhance healthcare outcomes and industry partnerships (Tracxn).
Sources
Kythera Labs
kytheralabs.com
Kythera Labs Partners with Databricks to Deliver More Accurate, Complete Insights to Healthcare and Life Sciences Companies
biospace.com
Careers at Kythera Labs | Healthcare Data Technologyed
kytheralabs.com
Kythera Labs
kytheralabs.com
Kythera Labs
kytheralabs.com
Kythera Labs Jobs + Careers | Built In
builtin.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors - Tracxn
tracxn.com
Kythera Labs Employee Directory
leadiq.com
Leadership
Kythera Labs Management and Leadership Team
The leadership team also includes Russ Sacks, Co-Founder and Executive VP of Innovation & Data Science, and Ryan Leurck, Director of Product. The company’s management team is composed of around six key members, with recent hires and leadership roles emphasizing growth in data science, healthcare analytics, and product development (The Org). As of early 2026, Kythera Labs continues to expand its executive team, focusing on strategic growth and innovation in healthcare data analytics (Tracxn).
Sources
Kythera Labs
cbinsights.com
Kythera | The Org
theorg.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors - Tracxn
tracxn.com
Kythera Labs, Inc. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas
people.equilar.com
Kythera Labs
kytheralabs.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors - Tracxn
tracxn.com
Matt Ryan - Executive Bio, Work History, and Contacts - Equilar ExecAtlas
people.equilar.com
Kythera Labs is a 2025 Inc. 5000 honoree
inc.com
Financials
Kythera Labs Financial Performance, Fundraising, M&A
Kythera Labs is also actively involved in M&A activities and strategic growth initiatives, including a $20 million funding round announced in November 2023 to accelerate the development of its Wayfinder data platform, which supports healthcare data analytics with over 320 million lives covered (BIP Ventures). The company's financial health indicators, such as its revenue and valuation, suggest a company in growth mode, leveraging substantial funding to expand its data technology offerings and partnerships within the healthcare industry.
Sources
Kythera Labs Moves Up the Ranks on the 2025 Inc. 5000 List of ...
kytheralabs.com
Kythera Labs Announces $20 Million Funding to Accelerate Growth ...
bipventures.vc
Kythera Labs Revenue, Funding & Valuation - Prospeo
prospeo.io
Kythera Labs Stock Price, Funding, Valuation, Revenue & Financial ...
cbinsights.com
Kythera Labs - Products, Competitors, Financials, Employees, Headquarters Locations
cbinsights.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors
tracxn.com
Hospitals and Health Systems Unlock Market Intelligence ...
kytheralabs.com
Kythera Labs - 2026 Company Profile, Team, Funding & Competitors - Tracxn
tracxn.com
Partnerships
Kythera Labs Partnerships, Clients and Vendors
Sources
Kythera Labs Builds Business on Spark Declarative Pipelines | Databricks
databricks.com
Kythera Labs
kytheralabs.com
Scipher Medicine and Kythera Labs Partner to Unlock New Insights into Autoimmune Disease-Specific Treatment - Scipher Medicine
sciphermedicine.com
Atropos Health and Kythera Labs Partner to Expand Access to Real-World Data to Advance Oncology
businesswire.com
How Kythera Labs, a Databricks Built-On Partner, saves $2M+/year using Delta Sharing | Databricks Blog
databricks.com
Technology Partners | Kythera Labs
kytheralabs.com
Kythera Labs
kytheralabs.com
Scipher Medicine and Kythera Labs Form Strategic Partnership to Advance Precision Medicine in Rheumatology
trial.medpath.com
Events
Kythera Labs Event Participations
Frequently Asked Questions
What does Kythera Labs's December 2023 CSO hire signal about its near-term product and revenue priorities?
The appointment of Glynn Dennis, Jr., Ph.D. — with prior experience at AstraZeneca and Genentech — as Chief Science Officer signals a deliberate pivot toward pharma and life sciences as a primary growth vector. Coupled with the $20 million funding round announced the same month, the hire suggests Kythera Labs is investing in scientific credibility and enterprise sales capacity needed to land large biopharma accounts, not just health system clients.
Does Kythera Labs's funding structure suggest a company on a healthy growth path or one that may be capital-constrained?
The picture is mixed and warrants scrutiny. Kythera Labs has raised approximately $40.86 million across four rounds, including a $20 million round in November 2023 and a follow-on Series A-II of $9.19 million in May 2024 — the latter being a relatively small tranche for a company with that total raise history. Reported annual revenue of roughly $2.8 million implies the company is still pre-scale relative to its capital deployed, and the rapid succession of rounds could indicate ongoing cash needs rather than opportunistic fundraising.
What does Kythera Labs's appearance on the 2025 Inc. 5000 — ranked 1,945th nationally and 38th in Nashville — actually tell a strategic buyer or investor about its growth rate?
The Inc. 5000 ranking confirms multi-year revenue compounding fast enough to clear the list's threshold, but a national rank of 1,945th with a 54% improvement in ranking year-over-year suggests growth acceleration is real yet still modest in absolute dollar terms given ~$2.8 million in reported revenue. For a corp-dev buyer, it signals the company is gaining commercial traction without yet reaching the scale that would make a revenue-based acquisition expensive — a potential window for a deal at favorable multiples.
How does Kythera Labs's partnership with Databricks as a Built-On Partner affect its competitive moat and exposure to platform risk?
The Databricks Built-On partnership deepens Kythera's technical differentiation — Wayfinder is purpose-built on the Databricks Data Intelligence Platform and uses Delta Sharing for governed, cost-efficient data distribution — which should accelerate enterprise sales through Databricks's channel. The flip side is meaningful platform concentration risk: if Databricks shifts partner economics, expands into adjacent analytics offerings, or is acquired, Kythera's product architecture and go-to-market are heavily exposed.
What do Kythera Labs's 2024–2025 partnerships with Atropos Health and Scipher Medicine reveal about its go-to-market strategy shift?
These partnerships mark a deliberate move up the value chain from data infrastructure provider to real-world evidence (RWE) enabler for therapeutic-area research — oncology via Atropos Health and autoimmune disease via Scipher Medicine. Rather than selling horizontal data pipelines, Kythera is embedding its high-fidelity datasets and proprietary transformation technologies into disease-specific research workflows, which implies a strategy of becoming a recurring data supply layer for precision medicine use cases rather than a one-time platform sale.
How does Kythera Labs's competitive position against IQVIA expose it to displacement risk in enterprise accounts?
IQVIA's scale, global data assets, and embedded relationships with large pharma and payer organizations represent a structurally disadvantaged matchup for Kythera in head-to-head enterprise deals. Kythera's realistic competitive angle is speed, flexibility, and Databricks-native architecture for mid-market life sciences and regional health systems that cannot afford or operationalize IQVIA's complexity — but any account that grows to enterprise scale becomes a churn risk as IQVIA and similar players compete on incumbency and breadth.
What does the concentration of Kythera Labs's event presence around Databricks conferences suggest about its channel dependency?
Kythera's visible event footprint — the Databricks Healthcare and Life Sciences Symposium in December 2023, the Databricks Data+AI Summit in July 2024, and the Data+AI World Tour NYC — is almost entirely within the Databricks ecosystem, suggesting the Databricks channel is currently the dominant pipeline-generation mechanism. This creates a concentration risk in lead generation and brand building; Kythera has limited documented presence at independent healthcare IT forums like HIMSS or JPMorgan Healthcare Conference, which could constrain its reach to buyers outside the Databricks orbit.
What does the gap between Kythera Labs's ~$40.86 million in total funding and ~$2.8 million in reported revenue imply about its burn rate and runway considerations?
A cumulative raise of roughly $40.86 million against $2.8 million in annual revenue implies a capital-intensity ratio that is high even by healthcare SaaS standards, suggesting either significant R&D and data infrastructure investment, a long enterprise sales cycle, or both. Without disclosed burn rate data, runway cannot be precisely calculated, but the May 2024 Series A-II follow-on — coming just six months after the $20 million round — raises questions about cash consumption speed that a potential partner or acquirer should diligence closely.
What does hiring Glynn Dennis with an AstraZeneca and Genentech background, rather than a health system or payer background, imply about which customer segment Kythera Labs is prioritizing for revenue growth?
The CSO's biopharma pedigree — AstraZeneca and Genentech specifically — signals that pharma and biotech, not hospitals or payers, are the near-term revenue growth priority. This aligns with the Atropos Health and Scipher Medicine partnership announcements, which target oncology and autoimmune research, and suggests Kythera is positioning Wayfinder as a real-world data platform for drug development and commercialization analytics rather than primarily for health system operations.
How does Tuva Health's focus on data normalization and quality testing position it as a threat to Kythera Labs's core value proposition?
Tuva Health directly challenges the foundational layer of Kythera's offering — claims and medical record normalization and enrichment — which is the prerequisite step before Wayfinder's analytics and ML capabilities can generate value. If Tuva becomes a standard preprocessing layer in enterprise healthcare data stacks, it could commoditize the data preparation work Kythera bundles into its platform, forcing Kythera to differentiate solely on downstream analytics and AI features rather than end-to-end data pipeline ownership.
What does the HPC partnership on price transparency data suggest about Kythera Labs's product expansion strategy beyond clinical analytics?
The partnership with HPC to convert price transparency data into actionable market insights indicates Kythera is deliberately expanding its dataset and use-case coverage into healthcare commercial and financial intelligence — beyond clinical and claims analytics. For a company with a ~34-person team, this breadth-versus-depth trade-off carries execution risk, but it also signals an intent to serve the strategic planning needs of healthcare executives, potentially opening hospital C-suite and payer strategy teams as new buyer personas alongside life sciences customers.
With a team of approximately 34 employees and a CSO, CTO, CFO, and EVP of Innovation on staff, is Kythera Labs's leadership-to-headcount ratio a sign of premature scaling or intentional enterprise positioning?
A six-person executive layer over a ~34-person total headcount — CEO, CSO, CTO, CFO, Co-Founder EVP, and Director of Product — is top-heavy by typical startup benchmarks and likely reflects a deliberate enterprise credentialing strategy rather than operational efficiency. In healthcare data and life sciences, buyers at large pharma and health systems evaluate vendor credibility heavily on executive pedigree, so the investment in named C-suite talent with AstraZeneca, Genentech, Trilliant, and Deloitte backgrounds functions as a sales and partnership enablement asset, even if it compresses margins at current revenue levels.
Powered by ForesightIQ · Competitive intelligence from digital exhaust